4,004 Shares in AstraZeneca Plc $AZN Bought by Sowell Financial Services LLC

Sowell Financial Services LLC purchased a new stake in AstraZeneca Plc (NYSE:AZN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 4,004 shares of the company’s stock, valued at approximately $647,000.

Several other institutional investors have also recently bought and sold shares of AZN. Mascoma Wealth Management LLC acquired a new position in AstraZeneca during the 1st quarter worth $26,000. Roxbury Financial LLC bought a new position in AstraZeneca in the 2nd quarter valued at $29,000. Resources Management Corp CT ADV acquired a new stake in shares of AstraZeneca in the 1st quarter valued at $35,000. Allied Private Wealth LLC acquired a new stake in shares of AstraZeneca in the 2nd quarter valued at $35,000. Finally, GK Wealth Management LLC acquired a new stake in shares of AstraZeneca in the 3rd quarter valued at $31,000. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

AZN has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Royal Bank Of Canada began coverage on AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Wall Street Zen upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings raised AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 26th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $206.67.

AstraZeneca Price Performance

AZN opened at $186.64 on Tuesday. The company has a fifty day moving average price of $164.90 and a two-hundred day moving average price of $180.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89. AstraZeneca Plc has a 52 week low of $153.41 and a 52 week high of $212.71. The firm has a market capitalization of $289.47 billion, a PE ratio of 26.40, a P/E/G ratio of 1.31 and a beta of 0.27.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The company had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. During the same quarter in the prior year, the business posted $2.38 EPS. The firm’s quarterly revenue was up 6.5% on a year-over-year basis. As a group, analysts anticipate that AstraZeneca Plc will post 10.21 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.